Study of Intestinal Permeability in Intensive Care Patients With Single or Multiple Organ Failure Related to Sepsis

What this Trial Is About

Multivisceral failure syndrome MVFS is a serious condition with a high risk of death, often linked to significant inflammation and infection in intensive care patients. This study investigates the role of increased intestinal permeability, which may allow bacteria to pass from the gut into the bloodstream, contributing to infection and poor outcomes. Researchers aim to understand how intestinal permeability relates to survival in patients with one or multiple organ failures caused by sepsis. Participants will be grouped based on the severity of their condition. One group includes patients with single organ failure and a SAPS2 score between 20 and 40, while the other includes those with multiple organ failures and a SAPS2 score between 60 and 80. Participants will receive an oral dose of a food coloring dye to measure intestinal permeability. The study is observational and will monitor these patients without altering their standard clinical care. Throughout the study, patients will be assessed for intestinal permeability and organ failure severity. The main outcome is survival and intestinal failure 90 days after inclusion. Researchers will also track changes in intestinal permeability over time. Data collection includes clinical monitoring, consent processes, and evaluation of feeding ability. The study starts in February 2025 and ends in April 2029.

Measurement of Intestinal Permeability in Intensive Care Patients With Single or Multiple Organ Failure